3/4
08:00 am
tara
Protara Therapeutics (TARA) is now covered by JPMorgan Chase & Co.. They set an "overweight" rating and a $27.00 price target on the stock.
Medium
Report
Protara Therapeutics (TARA) is now covered by JPMorgan Chase & Co.. They set an "overweight" rating and a $27.00 price target on the stock.
3/1
08:52 pm
tara
Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf [Yahoo! Finance]
Low
Report
Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf [Yahoo! Finance]
2/23
05:05 pm
tara
TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
High
Report
TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2/19
08:27 am
tara
Protara Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Protara Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
2/19
08:00 am
tara
Protara Therapeutics to Participate in Upcoming Investor Conferences
Medium
Report
Protara Therapeutics to Participate in Upcoming Investor Conferences
2/10
08:05 am
tara
Protara Therapeutics (NASDAQ:TARA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
Low
Report
Protara Therapeutics (NASDAQ:TARA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
2/2
04:05 pm
tara
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/22
08:00 am
tara
Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium
Low
Report
Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium
1/12
07:00 am
tara
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones
Medium
Report
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones
1/9
06:10 am
tara
Protara Therapeutics (NASDAQ:TARA) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
Low
Report
Protara Therapeutics (NASDAQ:TARA) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
1/7
08:10 am
tara
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support [Yahoo! Finance]
Medium
Report
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support [Yahoo! Finance]
1/7
08:00 am
tara
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/7
08:00 am
tara
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support
Medium
Report
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support
1/7
06:05 am
tara
Protara Therapeutics (NASDAQ:TARA) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
Medium
Report
Protara Therapeutics (NASDAQ:TARA) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
1/5
08:06 am
tara
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations [Yahoo! Finance]
Medium
Report
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations [Yahoo! Finance]
1/5
08:00 am
tara
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations
Medium
Report
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations
12/8
04:05 pm
tara
Protara Announces Closing of $75 Million Public Offering
Low
Report
Protara Announces Closing of $75 Million Public Offering